Thank You For Your Interest In The Regenexx Lumbar Degenerative Disc Disease (DDD) Study
Read all of the information below before submitting your application to be considered for participation.
We are seeking applicants for a new study being conducted by our research team in Broomfield, Colorado.
What is the purpose of our Study?
Our Research Team is conducting a study investigating how a series of two platelet-based treatments, made from a patient’s own blood, affects symptoms of lumbar degenerative disc disease (DDD).
What will Study Participants need to do?
Participants must be able to visit the Centeno-Schultz Clinic in Broomfield, CO for evaluation, two treatment procedures spaced 1-month apart, and two follow-up visits after the 2nd procedure, at a minimum.
Participants in the study will be randomly assigned to receive either two real treatments or two sham control procedures (to mimic spine injection treatment, although nothing is injected), in a 2:1 allocation. 28 participants will be assigned to the treatment group and 14 to the sham control group.
At the 3-month follow-up visit, all participants will be notified as to which study group they had been assigned. Participants assigned to the control group can then cross-over to the real treatment group at the 3-month follow-up visit.
Participant reported outcome surveys will also be completed before treatment, as well as at 1-, 3-, 6-, and 12-months.
What will selected Study Participants need?
All selected participants will need a lumbar MRI or lumbar flexion-extension x-ray to determine if they are a candidate for the lumbar degenerative disc disease (DDD) study.
What happens after you apply?
All prescreen applicants will be reviewed for candidacy by the research team and those who meet the study eligibility criteria to move forward will be notified individually.
Where can you read further details about the study?
You can read more details about the lumbar degenerative disc disease (DDD) study here.
How do I apply?
Fill out the form below and answer the prescreen questions: